Epigenetic silencing of MPDZ inhibits growth and progression of lung cancer [17] and epigenetic activation of FOXF1 confers cisplatin-resistant of NSCLC [18]. This evidence concerns the gene FOXF1 and non-small cell lung carcinoma.